Zevra Therapeutics (ZVRA) has shared an announcement.
Zevra Therapeutics, Inc. has announced that the FDA has extended its review of arimoclomol, a novel oral treatment for Niemann-Pick disease type C. The new deadline for the FDA’s decision is September 21, 2024, and the administration plans to discuss the drug at an upcoming advisory committee meeting. This development could be of interest to investors monitoring Zevra’s progress and the potential impact on its stock.
See more insights into ZVRA stock on TipRanks’ Stock Analysis page.
